Kong S L, Salto-Tellez M, Leong A P K, Chan Y H, Koay E S C
Department of Pathology, National University of Singapore, 10 Kent Ridge Crescent, Singapore 119260.
J Clin Pathol. 2005 Aug;58(8):839-44. doi: 10.1136/jcp.2004.023853.
Nodal expression of the carcinoembryonic antigen (CEA), cytokeratin 20 (CK20), and guanylyl cyclase C (GCC) genes was measured in tandem in patients with colorectal cancer (CRC) to assess whether there would be sufficient agreement between these markers in their ability to detect micrometastasis to qualify one of them as a universal marker, and whether frozen and paraffin wax embedded tissues would yield similar results.
One hundred and seventy five frozen lymph nodes (FT) and 158 formalin fixed, paraffin wax embedded lymph nodes (PET) from 28 CRC cases were analysed using gene specific quantitative real time polymerase chain reaction, carried out on the LightCycler system with SYBR Green chemistry.
There was significant disparity in positive detection of the three biomarkers in FT versus PET, with notable agreement achieved only for CEA (66.6%) in FT versus PET in Dukes' B disease, and between CK20 and GCC (44.6%) in FT, also in Dukes' B disease. One patient with full concordance in all three tumour markers with both tissue types suffered a relapse and died within two years of follow up.
There was considerable discordance in the positive detection of the three tumour markers in both tissue types (FT versus PET). This brings into question whether using a single tumour marker to detect micrometastasis in one tissue type (FT or PET) is adequately representative, and challenges the concept of universal markers for molecular CRC metastatic detection. Multiple tumour markers would predict more accurately the metastatic potential of Dukes' B CRCs.
对结直肠癌(CRC)患者的淋巴结进行癌胚抗原(CEA)、细胞角蛋白20(CK20)和鸟苷酸环化酶C(GCC)基因的串联检测,以评估这些标志物在检测微转移能力方面是否具有足够的一致性,从而使其中一种标志物有资格作为通用标志物,以及冷冻组织和石蜡包埋组织是否会产生相似的结果。
对28例CRC患者的175个冷冻淋巴结(FT)和158个福尔马林固定石蜡包埋淋巴结(PET),采用基因特异性定量实时聚合酶链反应进行分析,该反应在带有SYBR Green化学试剂的LightCycler系统上进行。
FT和PET中三种生物标志物的阳性检测结果存在显著差异,仅在Dukes B期疾病的FT与PET中,CEA的一致性较高(66.6%),同样在Dukes B期疾病的FT中,CK20和GCC之间的一致性为44.6%。一名在两种组织类型中三种肿瘤标志物检测结果完全一致的患者在随访两年内复发并死亡。
两种组织类型(FT与PET)中三种肿瘤标志物的阳性检测结果存在相当大的不一致性。这使得使用单一肿瘤标志物检测一种组织类型(FT或PET)中的微转移是否具有充分代表性受到质疑,并对分子CRC转移检测通用标志物的概念提出了挑战。多种肿瘤标志物能更准确地预测Dukes B期CRC的转移潜能。